Search

Displaying results 3171 - 3180 of 10000 in total
  1. Drug

    R1295

    go.drugbank.com/drugs/DB05122
    Experimental

    R1295 is an integrin antagonist currently in clinical trials for the treatment of rheumatoid arthritis. … Integrins are associated to the pathology seen in some of the autoimmune diseases such as rheumatoid arthritis.

  2. Drug

    Cobalt chloride

    go.drugbank.com/drugs/DB14206
    Approved

    Categories: Compounds used in a research, industrial, or household setting
  3. Drug

    Mecasermin

    go.drugbank.com/drugs/DB01277
    ApprovedInvestigational

    IGF-1 consists of 70 amino acids in a single chain with three intramolecular disulfide bridges and a molecular weight of 7649 daltons. … The rhIGF-1 protein is synthesized in bacteria (E. coli) that have been modified by the addition of the gene for human IGF-1.

  4. Drug

    Imidafenacin

    go.drugbank.com/drugs/DB09262
    Investigational

    Imidafenacin is an antispasmodic agent with anticholinergic effects. It antagonizes muscarinic receptors in the bladder to reduce the frequency of urination in the treatment of overactive bladder. … It is marketed in Japan under the tradenames Staybla by Ono Pharmaceutical and Uritos by Kyojin Pharmaceutical.

  5. Drug

    Meclizine

    go.drugbank.com/drugs/DB00737
    ApprovedInvestigational

    Meclizine is a histamine H1 antagonist with antiemetic and antivertigo properties. … [L6760] Commonly marketed under the brand name Antivert in the U.S., meclizine is available as oral tablets.

    Products: Trav-L-tabs, Dramamine - N
  6. Drug

    Rapacuronium

    go.drugbank.com/drugs/DB04834
    ApprovedWithdrawn

    Rapacuronium was withdrawn in 2001 in many countries due to risk of fatal bronchospasm.

  7. Drug

    Unexpanded umbilical cord-derived allogeneic CD34- hematopoietic stem cells

    go.drugbank.com/drugs/DB28348
    Approved

    in adult patients for whom a suitable donor is not available. … [L54146] Zemcelpro was granted conditional marketing authorization in the European Union in August 2025 for use in allogeneic hematopoietic stem cell transplantation following myeloablative conditioning

  8. Drug

    Mitoxantrone

    go.drugbank.com/drugs/DB01204
    ApprovedInvestigational

    An anthracenedione-derived antineoplastic agent.

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2E1 Substrates with a Narrow Therapeutic Index
  9. Drug

    Estriol

    go.drugbank.com/drugs/DB04573
    ApprovedInvestigationalVet approved

    It is however available in the United States by prescription filled only by compounding pharmacies. … A hydroxylated metabolite of estradiol or estrone that has a hydroxyl group at C3-beta, 16-alpha, and 17-beta position. Estriol is a major urinary estrogen.

    International brands: Synapause E
  10. Drug

    Aleglitazar

    go.drugbank.com/drugs/DB08915
    Investigational

    Aleglitazar is an investigational drug from the company Hoffmann–La Roche and is currently in a phase III clinical trial called ALECARDIO. … In the phase II clinical trial called SYNCHRONY, with type II diabetic patients, aleglitazar was able to control both lipid and glucose levels in a synergistic manner while also having limited side effects